VICTORION-INCEPTION and the Evolving Role of Inclisiran in ASCVD

The panelists review findings from the VICTORION-INCEPTION trial, which investigated the effects of initiating inclisiran during hospitalization for acute coronary syndrome (ACS) rather than waiting for outpatient follow-up. The experts note that the study demonstrated significantly improved LDL-C goal attainment and greater treatment persistence when inclisiran was started at discharge. By leveraging its twice-yearly dosing schedule, patients were more likely to maintain therapy adherence compared with traditional daily oral regimens. The trial also highlighted the practicality of integrating inclisiran into inpatient workflows, with strong feasibility and acceptance among both clinicians and patients. The panelists emphasize that this “start early, stay on” approach may help close the gap between evidence-based LDL-C targets and real-world implementation. They agree that VICTORION-INCEPTION supports the evolving role of inclisiran as an effective, durable option to improve long-term lipid control and secondary prevention outcomes in high-risk ASCVD populations.